指南与共识呼吸衰竭与机械通气消化、代谢与肾脏急症

美国感染病学会COVID-19诊断指南:抗原检测(2023年1月)

The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).
指南 / 共识 · Clin Infect Dis · 2024-01-01
一句话结论IDSA指南基于GRADE对SARS-CoV-2抗原检测提出10条诊断推荐:快速RT-PCR或实验室NAAT仍是诊断首选,分子检测不可及时抗原检测有助于识别感染者。

IDSA召集多学科专家组,系统综述截至2022年4月1日的同行评议文献,用GRADE方法评估证据确定性并制定SARS-CoV-2抗原检测的10条诊断推荐,覆盖有症状和无症状人群及单次与重复检测策略。FDA EUA抗原检测与NAAT相比特异性高、敏感性低至中等,敏感性取决于有无症状及有症状者症状出现后的检测时机;多数情况下阳性抗原结果无需确认即可处理。床旁检测与实验室检测结果可比,观察或未观察的自我采样结果相似;模型提示重复抗原检测较单次检测提高敏感性,但无实证数据。快速RT-PCR或实验室NAAT仍是诊断SARS-CoV-2感染的首选方法,分子检测不可及时抗原检测有助于识别感染者;数据不足以就抗原检测指导COVID-19患者解除隔离提出推荐。

要点

  • 快速RT-PCR或实验室NAAT仍是诊断SARS-CoV-2感染的首选检测方法(IDSA指南)。
  • 当及时分子检测不可获得或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者(IDSA指南)。
  • FDA EUA抗原检测与NAAT相比特异性高、敏感性低至中等,敏感性取决于有无症状及有症状者症状出现后的检测时机。
  • 多数情况下阳性抗原结果无需确认即可据以处理;床旁检测与实验室检测结果可比,观察或未观察的自我采样结果相似。
  • 模型提示重复抗原检测较单次检测提高敏感性,但无实证数据;数据不足以就抗原检测指导解除隔离提出推荐。

适用人群与场景

  • 有症状和无症状个体,用于医学和非医学场景下SARS-CoV-2抗原检测的最优使用决策。

处置流程与药物剂量

  • 快速RT-PCR或实验室NAAT仍是诊断SARS-CoV-2感染的首选检测方法。
  • 当及时分子检测不可 readily 获得或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者。
  • 多数情况下阳性抗原结果无需确认即可据以处理。
  • 床旁检测结果与实验室检测结果可比,观察或未观察的自我采样结果相似。
  • 模型提示重复抗原检测较单次检测提高敏感性,但无实证数据可供参考。
  • 数据不足以就抗原检测用于指导COVID-19患者解除隔离的效用提出推荐。

研究设计与关键结果

  • IDSA召集多学科专家组(感染病临床医生、临床微生物学家和系统文献综述专家),系统综述截至2022年4月1日的同行评议文献,采用GRADE方法评估证据确定性并制定推荐,共提出10条诊断推荐,覆盖有症状和无症状个体及单次与重复检测策略。
  • FDA EUA SARS-CoV-2抗原检测与NAAT相比特异性高、敏感性低至中等;抗原检测敏感性取决于有无症状,有症状者还取决于症状出现后的检测时机。
  • 多数情况下阳性抗原结果无需确认即可据以处理;床旁检测与实验室检测结果可比,观察或未观察的自我采样结果相似。
  • 模型提示重复抗原检测较单次检测提高敏感性,但无实证数据可供参考。
  • 快速RT-PCR或实验室NAAT仍是诊断SARS-CoV-2感染的首选检测方法;当及时分子检测不可 readily 获得或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者。
  • 数据不足以就抗原检测指导COVID-19患者解除隔离的效用提出推荐;支持抗原检测使用的现有证据总体质量被评定为极低至中等。

证据类型、等级与局限

  • 证据类型:IDSA指南,采用GRADE方法评估证据确定性并制定推荐;支持抗原检测使用的现有证据总体质量被评定为极低至中等。
  • 局限:模型提示重复抗原检测提高敏感性,但无实证数据可供参考;数据不足以就抗原检测指导解除隔离提出推荐。

对床旁实践的改变

  • 快速RT-PCR或实验室NAAT仍是诊断SARS-CoV-2感染的首选检测方法;仅当及时分子检测不可 readily 获得或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者。
  • 多数情况下阳性抗原结果无需确认即可据以处理;床旁检测与实验室检测结果可比,观察或未观察的自我采样结果相似。
  • 抗原检测敏感性取决于有无症状及有症状者症状出现后的检测时机。
  • 数据不足以就抗原检测指导COVID-19患者解除隔离提出推荐。

指南或共识出处

  • 美国感染病学会(IDSA)COVID-19诊断指南:抗原检测(2023年1月),发表于Clinical Infectious Diseases。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Immunoassays designed to detect SARS-CoV-2 protein antigens (Ag) are commonly used to diagnose COVID-19. The most widely used tests are lateral flow assays that generate results in approximately 15 minutes for diagnosis at the point-of-care. Higher throughput, laboratory-based SARS-CoV-2 Ag assays have also been developed. The number of commercially available SARS-CoV-2 Ag detection tests has increased rapidly, as has the COVID-19 diagnostic literature. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the literature and develop best-practice guidance related to SARS-CoV-2 Ag testing. This guideline is an update to the third in a series of frequently updated COVID-19 diagnostic guidelines developed by the IDSA. IDSA's goal was to develop evidence-based recommendations or suggestions that assist clinicians, clinical laboratories, patients, public health authorities, administrators, and policymakers in decisions related to the optimal use of SARS-CoV-2 Ag tests in both medical and nonmedical settings. A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review identified and prioritized clinical questions related to the use of SARS-CoV-2 Ag tests. A review of relevant, peer-reviewed published literature was conducted through 1 April 2022. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. The panel made 10 diagnostic recommendations that address Ag testing in symptomatic and asymptomatic individuals and assess single versus repeat testing strategies. US Food and Drug Administration (FDA) SARS-CoV-2 Ag tests with Emergency Use Authorization (EUA) have high specificity and low to moderate sensitivity compared with nucleic acid amplification testing (NAAT). Ag test sensitivity is dependent on the presence or absence of symptoms and, in symptomatic patients, on timing of testing after symptom onset. In most cases, positive Ag results can be acted upon without confirmation. Results of point-of-care testing are comparable to those of laboratory-based testing, and observed or unobserved self-collection of specimens for testing yields similar results. Modeling suggests that repeat Ag testing increases sensitivity compared with testing once, but no empirical data were available to inform this question. Based on these observations, rapid RT-PCR or laboratory-based NAAT remain the testing methods of choice for diagnosing SARS-CoV-2 infection. However, when timely molecular testing is not readily available or is logistically infeasible, Ag testing helps identify individuals with SARS-CoV-2 infection. Data were insufficient to make a recommendation about the utility of Ag testing to guide release of patients with COVID-19 from isolation. The overall quality of available evidence supporting use of Ag testing was graded as very low to moderate.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

参考来源

  1. Hayden MK, Hanson KE, Englund JA, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023). Clin Infect Dis. 2024. PMID: 36702617. doi:10.1093/cid/ciad032

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。